These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38782175)

  • 21. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.
    Kowdley KV; Luketic V; Chapman R; Hirschfield GM; Poupon R; Schramm C; Vincent C; Rust C; Parés A; Mason A; Marschall HU; Shapiro D; Adorini L; Sciacca C; Beecher-Jones T; Böhm O; Pencek R; Jones D;
    Hepatology; 2018 May; 67(5):1890-1902. PubMed ID: 29023915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
    Nevens F; Andreone P; Mazzella G; Strasser SI; Bowlus C; Invernizzi P; Drenth JP; Pockros PJ; Regula J; Beuers U; Trauner M; Jones DE; Floreani A; Hohenester S; Luketic V; Shiffman M; van Erpecum KJ; Vargas V; Vincent C; Hirschfield GM; Shah H; Hansen B; Lindor KD; Marschall HU; Kowdley KV; Hooshmand-Rad R; Marmon T; Sheeron S; Pencek R; MacConell L; Pruzanski M; Shapiro D;
    N Engl J Med; 2016 Aug; 375(7):631-43. PubMed ID: 27532829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
    J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
    J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
    Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
    Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from Germany.
    Wilde AB; Lieb C; Leicht E; Greverath LM; Steinhagen LM; Wald de Chamorro N; Petersen J; Hofmann WP; Hinrichsen H; Heyne R; Berg T; Naumann U; Schwenzer J; Vermehren J; Geier A; Tacke F; Müller T
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Finding the cure for primary biliary cholangitis - Still waiting.
    Tanaka A; Gershwin ME
    Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.
    Trauner M; Nevens F; Shiffman ML; Drenth JPH; Bowlus CL; Vargas V; Andreone P; Hirschfield GM; Pencek R; Malecha ES; MacConell L; Shapiro D
    Lancet Gastroenterol Hepatol; 2019 Jun; 4(6):445-453. PubMed ID: 30922873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
    Lammers WJ; van Buuren HR; Hirschfield GM; Janssen HL; Invernizzi P; Mason AL; Ponsioen CY; Floreani A; Corpechot C; Mayo MJ; Battezzati PM; Parés A; Nevens F; Burroughs AK; Kowdley KV; Trivedi PJ; Kumagi T; Cheung A; Lleo A; Imam MH; Boonstra K; Cazzagon N; Franceschet I; Poupon R; Caballeria L; Pieri G; Kanwar PS; Lindor KD; Hansen BE;
    Gastroenterology; 2014 Dec; 147(6):1338-49.e5; quiz e15. PubMed ID: 25160979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis.
    Roberts SB; Ismail M; Kanagalingam G; Mason AL; Swain MG; Vincent C; Yoshida EM; Tsien C; Flemming JA; Janssen HLA; Hirschfield GM; Hansen BE; Gulamhusein AF;
    Hepatol Commun; 2020 Sep; 4(9):1332-1345. PubMed ID: 32923836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obeticholic acid in primary biliary cholangitis: where we stand.
    Manne V; Kowdley KV
    Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA.
    Li J; Lu M; Zhou Y; Bowlus CL; Lindor K; Rodriguez-Watson C; Romanelli RJ; Haller IV; Anderson H; VanWormer JJ; Boscarino JA; Schmidt MA; Daida YG; Sahota A; Vincent J; Wu KH; Trudeau S; Rupp LB; Melkonian C; Gordon SC;
    Dig Dis Sci; 2022 Aug; 67(8):4170-4180. PubMed ID: 34499271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool.
    Murillo Perez CF; Gulamhusein A; Carbone M; Trivedi PJ; van der Meer AJ; Corpechot C; Battezzati PM; Lammers WJ; Cazzagon N; Floreani A; Parés A; Nevens F; Lleo A; Mayo MJ; Kowdley KV; Ponsioen CY; Dalekos GN; Gatselis NK; Thorburn D; Mason AL; Janssen H; Verhelst X; Bruns T; Lindor KD; Chazouillères O; Invernizzi P; Hansen BE; Hirschfield GM;
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e266-e273. PubMed ID: 33323757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.
    Yang C; Guo G; Li B; Zheng L; Sun R; Wang X; Deng J; Jia G; Zhou X; Cui L; Guo C; Zhou X; Leung PSC; Gershwin ME; Shang Y; Han Y
    Hepatol Int; 2023 Feb; 17(1):237-248. PubMed ID: 36309918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Wong LL; Hegade VS; Jones DEJ
    Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
    Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
    J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.